

## **DATA SUPPLEMENT**

**Title:** National Routine Adult Immunization Programs among World Health Organization Member States: An Assessment of Health Systems to Deploy Future SARS-CoV-2 Vaccines

**Supplemental Table 1. Countries Responding to Specific JRF Question Regarding Presence of an Adult Immunization Program, by Vaccine**

WHO Region	Hepatitis B Vaccine		Herpes Zoster Vaccine		Influenza Vaccine		Pneumococcal Conjugate Vaccine		Pneumococcal Polysaccharide Vaccine		Any of the Assessed Vaccines	
	n	%	n	%	n	%	n	%	n	%	n	%
Africa (n=47)	3	6.4	0	0.0	3	6.4	41	87.2	0	0.0	41	87.2
Americas (n=35)	31	88.6	4	11.4	32	91.4	28	80.0	16	45.7	35	100.0
Eastern Mediterranean (n=21)	7	33.3	1	4.8	13	61.9	16	76.2	4	19.1	20	95.2
Europe (n=53)	37	69.8	31	58.5	50	94.3	48	90.6	34	64.2	52	98.1
South-East Asia (n=11)	0	0.0	0	0.0	1	9.1	5	45.5	0	0.0	6	54.6
Western Pacific (n=27)	5	18.5	2	7.4	15	55.6	19	70.4	5	18.5	22	81.5
Worldwide (n=194)	83	42.8	38	19.6	114	58.8	157	80.9	59	30.4	176	90.7

**Supplemental Table 2. Economic Characteristics of WHO Member States in 2018, by Reported National Adult Immunization Programs**

	HepB program					HZV program					Influenza vaccination program					PCV program					PPSV program				
	Yes (N=72)		No (N=121)		P-value <sup>1</sup>	Yes (N=17)		No (N=175)		P-value	Yes (n=113)		No (N=79)		P-value	Yes (N=16)		No (N=176)		P-value	Yes (N=35)		No (N=157)		P-value
	n	%	n	%		n	%	n	%		n	%	n	%		n	%	n	%		n	%	n	%	
WB Income group <sup>2</sup>																									
Low income (n=34)	0	0.0	34	28.1	<0.001	0	0.0	34	19.4	<0.001	1	0.9	33	41.8	<0.001	0	0.0	34	19.3	<0.001	0	0.0	34	21.7	<0.001
Lower-middle income (n=46)	7	9.9	39	32.1		0	0.0	46	26.3		15	13.3	31	39.2		0	0.0	46	26.1		2	5.7	44	28.0	
Upper middle income (n=56)	29	40.9	27	22.3		1	5.9	55	31.4		42	37.2	14	17.7		0	0.0	56	31.8		6	17.1	50	31.9	
High income (n=56)	35	49.3	21	17.4		16	94.1	40	22.9		55	48.7	1	1.3		16	100.0	40	22.7		27	77.1	29	18.5	
Gavi eligible	Yes (N=72)		No (N=123)		P-value <sup>1</sup>	Yes (N=17)		No (N=177)		P-value	Yes (n=114)		No (N=80)		P-value	Yes (N=16)		No (N=178)		P-value	Yes (N=35)		No (N=159)		P-value
	n	%	n	%		n	%	n	%		n	%	n	%		n	%	n	%		n	%	n	%	
Yes (n=48)	1	1.4	47	38.2	<0.001	0	0.0	48	27.1	0.01	0	0.0	48	60.0	<0.001	0	0.0	48	27.0	0.02	0	0.0	48	31.8	<0.001
No (n=146)	70	98.6	76	61.8		17	100.0	129	72.9		114	100.0	32	40.0		16	100.0	130	73.0		43	100.0	103	68.2	

Abbreviations: HepB = Hepatitis B vaccine; HZV= Herpes Zoster Vaccine; PCV = pneumococcal conjugate vaccine; PPSV = pneumococcal polysaccharide vaccine; HPV= human papillomavirus vaccine

1. p-value for trend (World Bank income group comparisons)
2. Niue and The Cook Islands, not World Bank member countries, are excluded from the income categories
3. Reference category
4. Chi-square test (Gavi eligibility comparisons)

**Supplemental Table 3. Median per Capita Health Care Expenditures of WHO Member States in 2018, by reported National Adult Immunization Program**

Adult Vaccination program	Has Program	Statistic	Median per capita health care expenditure (USD) <sup>1</sup>
HepB program	Yes (N=68)	Median (IQR)	884 (412, 2118)
	No (N=116)	Median (IQR)	195 (45, 732)
		<b>p-value<sup>2</sup></b>	<b>&lt;0.001</b>
HZV program	Yes (N=17)	Median (IQR)	2,882 (1,845, 3,465)
	No (N=167)	Median (IQR)	314 (62, 900)
		<b>p-value</b>	<b>&lt;0.001</b>
Influenza vaccination program	Yes (N=109)	Median (IQR)	933 (482, 2,226)
	No (N=75)	Median (IQR)	59 (25, 196)
		<b>p-value</b>	<b>&lt;0.001</b>
PCV program	Yes (N=16)	Median (IQR)	2,221 (1335, 3510)
	No (N=168)	Median (IQR)	319 (63, 884)
		<b>p-value</b>	<b>&lt;0.001</b>
PPSV program	Yes (N=43)	Median (IQR)	1,676 (930, 3,331)
	No (N=151)	Median (IQR)	208 (52, 564)
		<b>p-value</b>	<b>&lt;0.001</b>

HepB= hepatitis B; HZV = Herpes zoster virus vaccine; PCV = pneumococcal conjugate vaccine; PPSV= pneumococcal polysaccharide vaccine

<sup>1</sup>Excluding 10 countries with missing health care expenditure data

<sup>2</sup>Kruskal-Wallis test for difference in medians

**Supplemental Table 4. Immunization Program Characteristics of WHO Member states in 2018, by reported National Adult Immunization Programs**

Introduced Hepatitis B birth dose	n	HepB program					HZV Program					Influenza vaccine program					PCV program					PPSV program				
		Yes		No		p-value	Yes		No		p-value	Yes		No		p-value	Yes		No		p-value	Yes		No		p-value
		n	%	n	%		n	%	n	%		n	%	n	%		n	%	n	%		n	%	n	%	
Yes	128	53	41.4	75	58.6	0.05	14	10.9	114	89.1	0.14	91	71.1	37	28.9	<0.001	12	9.4	116	90.6	0.43	27	21.1	101	78.9	0.12
No	66	18	27.3	48	72.7		3	4.6	63	95.5		23	34.9	43	65.2		4	6.1	62	93.9		8	12.1	58	87.9	
Introduced HPV																										
Yes	90	50	55.6	40	44.4	<0.001	14	10.9	114	89.1	<0.001	73	81.1	17	18.9	<0.001	13	14.4	77	85.6	<0.01	29	32.2	61	67.8	<0.001
No	104	21	20.2	83	79.8		17	18.9	73	81.1		41	39.4	63	60.6		3	2.9	101	97.1		6	5.8	98	94.2	
Introduced Rotavirus vaccine																										
Yes	101	40	39.6	61	60.4	0.37	13	12.9	88	87.1	0.04	56	55.5	45	44.6	0.33	10	9.9	91	90.1	0.38	23	22.8	78	77.2	0.07
No	93	31	33.3	62	66.7		4	4.3	89	95.7		58	62.4	35	37.6		6	6.5	87	93.6		12	12.9	81	87.1	
Functioning NITAG <sup>2</sup>																										
Yes	114	47	41.2	67	58.8	0.11	14	12.3	100	87.7	0.04	78	68.4	36	31.6	<0.01	13	11.4	101	88.6	0.06	23	20.2	91	79.8	0.36
No	80	24	30.0	56	70.0		3	3.8	77	96.3		36	45.0	44	55.0		3	3.8	77	96.3		12	15.0	68	85.0	
Eliminated maternal and neonatal tetanus																										
Yes	180	71	39.4	109	60.0	<0.01	17	9.4	163	90.6	0.23	114	63.3	66	36.7	<0.001	16	8.9	164	91.1	0.24	35	19.4	145	80.6	0.07
No	14	0	0.0	14	100.0		0	0.0	14	100.0		0	0.0	14	100.0		0	0.0	14	100.0		0	0.0	14	100.0	
DTP coverage ≥95% nationally																										
Yes	84	39	46.4	45	53.6	0.01	7	8.3	77	91.7	0.85	62	73.8	22	26.2	<0.001	10	11.9	74	88.1	<0.01	18	21.4	66	78.6	0.28
No	110	32	29.1	78	70.9		10	9.1	100	90.9		52	47.3	58	52.7		6	5.5	104	94.6		17	15.5	93	84.6	

HepB = Hepatitis B vaccine; HZV= Herpes Zoster Vaccine; PCV = pneumococcal conjugate vaccine; PPSV = pneumococcal polysaccharide vaccine; HPV= human papillomavirus vaccine; DTP= diphtheria, tetanus and pertussis containing vaccine

1. Chi-square test

2. National Immunization Technical Advisory Group; limited to n=134 countries for which this information was available

**Supplemental Table 5A. Analysis of Immunization Program Characteristics associated with the presence of one or more adult vaccination programs**

	Any adult vaccination program		
	Yes (N=120)		aOR <sup>1</sup> (95% CI)
	n	%	
Introduced Hepatitis B birth dose			
Yes	94	78.3	3.26 (1.2, 9.0)
No	26	21.7	
Introduced HPV			
Yes	76	63.3	3.48 (1.3, 9.4)
No	44	36.7	
Introduced Rotavirus vaccine			
Yes	60	50.0	1.13 (0.4, 2.9)
No	60	50.0	
Functional NITAG <sup>2</sup>			
Yes	82	68.3	6.74 (2.3, 19.7)
No	38	31.7	
Eliminated maternal and neonatal tetanus			
Yes	120	100.0	n/a
No	0	0.0	
DTP coverage $\geq$ 95% nationally			
Yes	66	55.0	1.57 (0.6, 3.9)
No	54	45.0	
HIC or UMIC2			
Yes	100	84.0	19.28 (6.5, 57.7)
No	19	16.0	

1. Adjusted for all other characteristics in the table

2. Two countries without world bank income classifications excluded from denominator

**Supplemental Table 5B. Analysis of Immunization Program Characteristics associated with the presence of individual adult vaccination programs**

	Adult HepB program			Adult HZV Program			Adult influenza vaccination program			Adult PCV Program			Adult PPSV Program		
	Yes (N=71)			Yes (N=17)			Yes (N=114)			Yes (N=16)			Yes (N=35)		
	n	%	aOR (95% CI)	n	%	aOR (95% CI)	n	%	aOR <sup>1</sup> (95% CI)	n	%	aOR (95% CI)	n	%	aOR (95% CI)
Introduced Hepatitis B birth dose															
Yes	53	74.7	1.0 (0.4, 2.3)	14	82.4	2.0 (0.5, 8.5)	91	79.8	3.7 (1.4, 10.1)	12	75.0	0.9 (0.2, 3.1)	27	77.1	1.3 (0.5, 3.4)
No	18	25.4		3	17.7		23	20.2		4	25.0		8	22.9	
Introduced HPV															
Yes	50	70.4	1.9 (0.9, 4.1)	17	100.0	n/a	73	64.0	3.4 (1.3, 9.0)	13	81.3	1.9 (0.4, 7.8)	29	82.9	3.3 (1.2, 9.3)
No	21	29.6		0	0.0		41	36.0		3	18.8		6	17.1	
Introduced Rotavirus vaccine															
Yes	40	56.3	1.8 (0.9, 3.9)	13	76.5	2.5 (0.7, 9.6)	56	49.1	0.95 (0.4, 2.4)	10	62.5	2.1 (0.6, 7.1)	23	65.7	2.18 (0.9, 5.3)
No	31	43.7		4	23.5		58	50.9		6	37.5		12	34.3	
Functional NITAG <sup>2</sup>															
Yes	47	66.2	1.5 (0.7, 3.1)	14	82.4	3.17 (0.8, 12.8)	78	68.4	5.6 (2.1, 15.3)	13	81.3	3.1 (0.8, 11.9)	23	65.7	1.2 (0.5, 2.8)
No	24	33.8		3	17.7		36	31.6		3	18.8		12	34.3	
Eliminated maternal and neonatal tetanus															
Yes	71	100.0	n/a	17	100.0	n/a	114	100.0	n/a	16	100.0	n/a	35	100.0	n/a
No	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
DTP coverage ≥95% nationally															

Yes	39	54.9	1.2 (0.6, 2.1)	7	41.2	0.7 (0.2, 2.3)	62	54.4	1.2 (0.5, 2.8)	10	62.5	1.7 (0.5, 5.5)	18	51.4	1.0 (0.4, 2.3)
No	32	45.1		10	58.8		52	45.6		6	37.5		17	48.6	
HIC or UMIC <sup>2</sup>															
Yes	64	90.1	10.1 (3.6,28.1)	17	100.0	n/a	97	85.8	17.3 (6.2, 48.4)	16	100.0	n/a	33	94.3	9.2 (1.9, 45.1)
No	7	9.9		0	0.0		16	14.2		0	0.0		2	5.7	

1. Adjusted for all other characteristics in the table
2. Two countries without world bank income classifications excluded from denominator